ArticleFrontiers in digital health2025
Smartphone apps in rare disease care: a Dutch perspective on effective implementation.
Article in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Smartphone-based health applications offer promising opportunities for personalized and continuous monitoring in healthcare. However, many apps remain confined to research settings and are never implemented in clinical practice. Moreover, the development and implementation of apps for rare diseases is significantly lagging behind. This perspective outlines six key themes critical to the successful development and implementation of health apps, drawing on insights from Dutch stakeholders. These include: stakeholder collaboration, development, ownership, financing, integration into hospital-based care, and patient use. Our perspective additionally discusses specific barriers, including regulatory constraints, funding challenges, and usability limitations, alongside facilitators such as co-creation with end users, early stakeholder involvement, implementation planning, and leveraging existing care networks. Specific challenges for rare diseases, such as limited patient populations, funding constraints, and difficulties in clinical validation and regulatory compliance, are also addressed, with potential solutions proposed. This perspective offers concrete recommendations to support the transition of health apps from research to clinical practice. Sustainable implementation requires early and ongoing stakeholder engagement, flexible strategies adapted to small-scale contexts, a strong focus on end users' needs, and an impact-driven implementation plan already established at the start of development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.